Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Name Reactions for One Thousand, Alex | Main | Here's A Shovel. Could You Dig Yourself In Some More? »

January 30, 2006

Forecast: Rain, Eventually

Email This Entry

Posted by Derek

Business Week, whose reporting on the industry I've been uncomplimentary about in the past, is saying that year-end earnings reports show that European drugmakers are moving past the American-based ones in profitability.

And that's probably true, for 2005 anyway. Merck (and to a lesser extent, Pfizer) got hammered last year, and several other companies turned in pretty unremarkable performances. But the comparison that the magazine is making is, for the most part, an artifact. US companies had some big sellers a few years ago, and the European companies looked like they were falling behind. Now the patent expirations are looming (and some bad news has hit), so the situation is reversing. It happens.

It doesn't make much sense to divide drug companies up just by location of their headquarters in the first place. GlaxoSmithKline, for example, is a British company, but their culture seems more or less identical to that of the American companies. And I'd have to think that Novartis would have more in common with another big outfit like Merck than it would with a smaller European company. I'm not saying that the European companies don't tend to have a different way of doing things, because on average I think that they do. It's just that the comparisons aren't as easy to do as you'd think.

The BW piece goes on about various drug recalls on this side of the ocean, but they make things look more dramatic by not including some of the other European companies like Bayer (which went through a painful recall of its statin drug a few years ago). The article also makes much out of Sanofi-Aventis and their prospects for Acomplia (rimonabant) this year - but how would Aventis look if they were still on their own? That merger issue makes the comparison with the US companies rather complicated, too, since Pfizer's biggest drugs were acquired through buying other companies.

The article doesn't try to draw many larger conclusions about how the European companies might be doing things differently or how the American ones got into trouble. And it's a good thing, too, because it's hard to come up with any generalizations that make sense. (You might be able to sell a specialty-markets versus direct-to-consumer difference, but the piece doesn't bother trying). What readers are left with some sort of weather report: "It was cold a few days ago, but now it's not. Today it's raining, but tomorrow, who knows?".

Comments (0) + TrackBacks (0) | Category: Business and Markets


COMMENTS
POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Scripps Update
What If Drug Patents Were Written Like Software Patents?
Stem Cells: The Center of "Right to Try"
Speaking of Polyphenols. . .
Dark Biology And Small Molecules
How Polyphenols Work, Perhaps?
More On Automated Medicinal Chemistry
Scripps Merging With USC?